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Abstract
Background CARD15 mutations alter bowel immunity
and increase susceptibility to Crohn0s disease (CD). How-
ever, the relation between these mutations and Crohn0s
perianal fistulas has not been fully clarified.
Aims To assess whether CARD15 mutations are associ-
ated with risk of developing Crohn’s perianal fistulas and
whether these mutations are predictors of the response of
perianal fistulas to antibiotics.
Methods CARD15 mutations were investigated in 203
consecutive CD patients. Presence/absence of history of
perianal fistula was recorded. Patients with history of per-
ianal fistula were divided into two groups (with/without
CARD15 mutations), and response to antibiotics was
evaluated in both groups.
Results Of the 203 patients, 60 (29.6%) showed at least
one CARD15 mutation and 55 (27.1%) had history of
perianal fistula. History of perianal fistula was identified in
13 (21.7%) patients with mutations and in 42 (29.4%)
patients without mutations (P = 0.260). Mean age at
diagnosis of first perianal fistula was similar in patients
with/without CARD15 mutations (28.7 ± 9.8 versus 29.7 ±
10.1 years, P = 0.758). Average time between disease
onset and diagnosis of first perianal fistula was also similar
in the two groups (4.6 ± 5.1 versus 5.0 ± 5.9 years, P =
0.816). Response of perianal fistulas to antibiotics (met-
ronidazole alone or combined with ciprofloxacin) was
significantly higher in patients without CARD15 mutations
(7.7% versus 40.5%, P = 0.041).
Conclusions In CD, CARD15 mutations are not associ-
ated with risk of developing perianal fistulas or with time
of their outbreak. Nevertheless, patients with perianal fis-
tulas and CARD15 mutations showed worse response to
antibiotics.
Keywords CARD15  Crohn’s disease  Perianal fistulas 
Antibiotics
Introduction
The transmural inflammation characteristic of Crohn0s
disease (CD) predisposes patients to formation of fistulas.
Up to 43% of CD patients will develop perianal fistulas,
with a significant increase of disability and direct and
indirect costs, and a decrease in perceived quality of life
[1–4]. The risk of developing Crohn0s perianal fistulas
increases when the disease involves the distal bowel.
Patients with colonic CD, particularly those with rectal
involvement, have significantly higher incidence of peria-
nal fistulas than patients without colonic involvement [2].
Indeed, only 12% of patients with isolated ileal disease
develop perianal fistulas, compared with 92% of patients
with rectal involvement [2]. These results were recently
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corroborated by a large cross-sectional study carried out in
our country [5].
The American Gastroenterological Association technical
review on perianal CD recommended division of fistulas into
either simple or complex [6]. A simple fistula is superficial
(intersphincteric or low transsphincteric), painless, with a
single external opening and no evidence of rectovaginal
involvement or anorectal stricture [6]. In contrast, a complex
fistula is located high (high transsphincteric, extrasphincteric
or suprasphincteric), may be associated with pain, can
potentially involve multiple external openings, and may be
associated with rectovaginal fistula and/or anorectal stricture
[6]. This is a clinically important differentiation, because
several studies have shown better outcomes for patients with
simple fistula tracts [7–10].
Although treatments for fistulizing perianal CD have
evolved greatly over the past decade, antibiotics remain
widely used and are the recommended first-line treatment
for these patients, despite the absence of controlled studies
to support this approach [4, 11]. However, the response rate
of perianal fistulas to antibiotics is only around 50%
[12–16]. Furthermore, ineffective or inappropriate treat-
ment of perianal fistula may lead to recurrence of the fistula
or can result in the fistula progressing from simple to
complex form [17]. Complex fistulas are more difficult to
treat, have decreased healing rates, and are associated with
less successful outcomes [7–10]. For these reasons, it
would be very important to have predictors of the response
of perianal fistulas to antibiotics.
The specific pathogenesis of Crohn0s perianal fistulas is
unknown, but luminal bacteria seem to play a role in their
development and maintenance [18]. Since CARD15 muta-
tions increase susceptibility to CD and appear to change the
host response to luminal bacteria, it is reasonable to specu-
late on a possible connection between this gene and perianal
fistulas [19–24]. However, there are few studies on the
correlation between CARD15 mutations and development of
Crohn0s perianal fistulas, and they provided conflicting data
[25, 26]. There is also limited information on whether
CARD15 variants may influence the response of perianal
fistulas to treatment, namely to antibiotics [16]. In this study,
we assessed whether CARD15 mutations are associated with
risk of developing Crohn0s perianal fistulas and whether
these mutations are predictors of the response of perianal
fistulas to antibiotics (metronidazole and/or ciprofloxacin).
Methods
Patients
Two hundred three consecutive patients with CD [87 males,
age (mean ± standard deviation) = 35.9 ± 10.2 years;
116 females, age (mean ± standard deviation) = 37.1 ±
7.6 years] were included in this investigation. Diagnosis of
CD was based on accepted clinical, endoscopic, radiologic,
and histologic criteria [27].
Ethical approval for this research was given by the local
Ethics Committee. Each patient was informed of the nature
of the study and signed the informed consent form, in
accordance with the Declaration of Helsinki.
Sample DNA Extraction
Blood samples were collected with standard venipuncture
technique using ethylenediamine tetraacetic acid (EDTA)-
containing tubes. Genomic DNA was isolated from whole
blood using the QIAamp Mini Kit (QIAGEN GmbH,
Germany).
Genotyping
All participants were genotyped for the three major
CARD15 mutations: R702W (SNP8), G908R (SNP12), and
3020insC (SNP13). Genotyping was performed by real-
time polymerase chain reaction (PCR): variants R702W
and G908R using HybProbe (FRET), and variant 3020insC
using SimpleProbe. R702W variant was amplified and
detected using the forward primer 50-AgCCgCACAACCT
TAgATCAC-30, the reverse primer 50-gCgggCACAggCAT
AgC-30, the anchor probe 50-LC Red640-gTCTggCACTC
AgCCAgCAggCCCC-PH, and the donor probe 50-gCgC
CAgAgCAgggCCTTCTCA-FL. For assay of the G908R
mutation, 50-gCACATATCAggTACTCACTgACACT-30
was used as the forward primer, 50-TTACCTgAgCCACCT
CAAgC-30 as the reverse primer, 50-LC Red705-CTgAA
AAggCCAAAAgAgTCAACAgAC-PH as the anchor probe,
and 50-CCACTCTgTTgCCCCAgAA-FL as the donor probe.
To detect the 3020insC variant, PCR was carried out using the
forward primer 50-gACAggTgggCTTCAgTAgA-30, the
reverse primer 50-TgAggTTCggAgAgCTAAAACAg-30,
and the simple probe 50-CTgCAggCCCCTTgAAAg-FLQ.
The reaction mixture consisted of 18 ll PCR master mix
plus 2 ll DNA of each patient. The PCR master mix for the
R702W variant included 5.0 mM MgCl2, 19 LightCycler
DNA master hybridization probes (Roche, Mannheim,
Germany), 0.5 lM each primer, and 0.1 lM each of fluo-
rescein and LC-Red-640-labeled probe. Cycling parame-
ters consisted of 1 cycle of 95C for 2 min, followed by
amplification for 45 cycles of 95C for 0 s, 55C for 10 s,
and 72C for 5 s. A melting curve was created by mea-
suring the fluorescence signal generated with the following
profile: 95C for 5 s, 50C for 10 s, and 90C for 0 s with a
slope 0.4C/s transition. The PCR master mix for the
G908R mutation included 2.5 mM MgCl2, 19 LightCycler
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DNA master hybridization probes (Roche, Mannheim,
Germany), 0.5 lM each primer, and 0.2 lM each of fluo-
rescein and LC-Red-705-labeled probe. Cycling parame-
ters consisted of 1 cycle of 95C for 2 min, followed by
amplification for 40 cycles of 95C for 10 s, 57C for 8 s,
and 72C for 17 s. A melting curve was created by mea-
suring the fluorescence signal generated with the following
profile: 95C for 20 s, 40C for 20 s, and 85C for 0 s with
a slope 0.2C/s transition. Finally, the PCR master mix for
the 3020insC variant included 2.5 mM MgCl2, 19 Light-
Cycler DNA master hybridization probes (Roche, Mann-
heim, Germany), 0.2 lM forward primer, 0.5 lM reverse
primer, and 0.2 lM simple probe. Cycling parameters
consisted of 1 cycle of 95C for 2 min, followed by
amplification for 40 cycles of 95C for 10 s, 55C for 10 s,
and 72C for 20 s. A melting curve was created by mea-
suring the fluorescence signal generated with the following
profile: 95C for 20 s, 40C for 20 s, and 85C for 0 s with
a slope 0.2C/s transition. Sterile water was used as a
negative control. The change of fluorescence was con-
verted to a melting peak (Tm) by plotting the negative
derivative of the fluorescence signal corresponding to the
temperature (-dF/dT) using the LightCycler software.
The sequence variations of the PCR products were
confirmed by DNA sequencing.
Medical History And Outcomes
This information was obtained from the inflammatory
bowel disease database of our department and comple-
mented by a review of patients’ files. Initially we recorded
whether patients developed perianal fistulas before or
during follow-up. Then, in patients with history of perianal
fistula, we recorded the following: gender, current age,
disease location, type of fistulas (simple or complex), age
at diagnosis of first perianal fistula, time between disease
onset and diagnosis of first perianal fistula, antibiotics used
in treatment of perianal fistulas, concomitant medication,
and clinical response of perianal fistulas to antibiotic
therapy.
Antibiotic therapy was defined as use of metronidazole
and/or ciprofloxacin for at least 1 week. Metronidazole was
used in all patients (dosage: median 980 mg/day, range
750–1,500 mg/day) and 28 patients also received cipro-
floxacin (dosage: median 970 mg/day, range 500–
1,000 mg/day).
Response was defined as absence of fistula drainage,
even after compression, for at least 4 weeks, according to
the Fistula Drainage Assessment definition of remission
and following the current recommendations for efficacy
endpoints in clinical trials [28, 29].
Clinical and laboratory investigators were blinded to
genetic results and to clinical data, respectively.
Definition of Groups
Patients with history of perianal fistula were divided into
two groups according to presence or absence of CARD15
variants (with/without CARD15 mutations). These groups
were compared for: age at diagnosis of first perianal fistula,
time between disease onset and diagnosis of first perianal
fistula, and clinical response of perianal fistulas to antibi-
otic therapy.
Statistical Analysis
Categorical variables were expressed as frequency and
percentage, and corresponding contingency tables were
analyzed with Pearson’s chi-square test or Fisher0s exact
test, as appropriate. Odds ratios (OR) were determined with
95% confidence intervals (95% CI).
Continuous variables were summarized using
mean ± standard deviation. These variables were tested
for normal distributions using the Kolmogorov-Smirnov
test. The Student’s t test was employed to compare means
of continuous variables and normally distributed data;
otherwise, the Mann-Whitney U test was applied.
Only P values \0.05 were considered significant.
All variants studied were in Hardy-Weinberg equilibrium.
Data were analyzed using the Statistical Package for
Social Sciences (SPSS version 17.0; SPSS Inc., Chicago,
IL, USA) software for Windows.
Results
A total of 203 patients were studied. CARD15 variants
were detected in 60 patients (29.6%), comprising 28 het-
erozygotes for SNP8 (13.8%), 13 heterozygotes for SNP13
(6.4%), 12 heterozygotes for SNP12 (5.9%), 3 compound
heterozygotes [2 (1.0%) for SNP8/SNP12, 1 (0.5%) for
SNP12/SNP13], and 4 homozygotes [2 (1.0%) for SNP13,
1 (0.5%) for SNP8, 1 (0.5%) for SNP12]. History of per-
ianal fistula was identified in 55 (27.1%) patients, including
13 (21.7%) of the 60 patients with mutations and 42
(29.4%) of the 143 patients without mutations (P = 0.865).
Mean age at diagnosis of first perianal fistula was similar
in the two groups (28.7 ± 9.8 years in patients with
CARD15 mutations versus 29.7 ± 10.1 years in patients
without CARD15 mutations, P = 0.758). Average time
between disease onset and diagnosis of first perianal fistula
was also similar in the two groups (4.6 ± 5.1 years in
patients with CARD15 mutations versus 5.0 ± 5.9 years in
patients without CARD15 mutations, P = 0.816).
The overall clinical response of perianal fistulas to
antibiotics was 32.7% (18 of the 55 patients). This response
was observed in 1 patient with CARD15 mutation and in 17
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patients without CARD15 mutations (7.7% versus 40.5%,
P = 0.041) (Table 1). The odds ratio, calculated for the
probability of response to antibiotics in patients without
mutations compared with patients with mutations, was 8.16
(95% confidence interval 0.97–68.74). This means that the
probability of response of perianal fistulas to antibiotics in
CD patients without CARD15 mutations is 8.16 higher than
that of patients with mutation of this gene (Table 1). The
only patient with CARD15 mutation who responded to
antibiotic therapy was a heterozygote for SNP8. The anti-
biotics used, as well as the dosage and duration of therapy,
were similar in patients with and without CARD15 muta-
tions (Table 2). Likewise we did not detect any significant
differences in concomitant medication (Table 3). Finally,
we found that patients with and without CARD15 muta-
tions did not significantly differ with regard to proportion
of simple/complex fistulas (1.5 in patients with CARD15
mutations versus 1.7 in patients without CARD15 muta-
tions, P = 0.921) or incidence of rectal mucosa involve-
ment by CD (66.6% and 55.0% in patients with and
without CARD15 mutations, respectively; P = 0.519).
The 37 patients with perianal fistulas who did not
responded to antibiotics then received the following treat-
ments: surgery (26 patients), infliximab (8 patients), and
combination surgery ? infliximab (3 patients).
Discussion
Perianal fistulas are a common manifestation of CD that
can lead to significant morbidity and even proctectomy
[1–4].
As it is generally assumed that CD is a heterogeneous
disease that is composed of subsets of disorders representing
different pathogenic mechanisms, numerous genotype–
phenotype studies have been performed reporting the asso-
ciation of CARD15 variants with multiple characteristics of
localization and behavior of CD [25, 26, 30–36]. A major
problem in comparing these studies is the heterogeneity of
phenotypic classifications presented, especially with regard
to penetrating behavior. Some classification schemes,
according to the Vienna classification, include perianal fis-
tulas in fistulizing behavior, whereas others, following the
Montreal classification, regard anal involvement as a dif-
ferent entity, separate from intra-abdominal penetrating
disease [25, 26, 30–38].
Few studies have specifically evaluated the correlation
between CARD15 mutations and Crohn0s perianal fistulas,
and their results were controversial. Henckaerts et al., in a
recent study involving 875 CD patients, concluded that
absence of CARD15 variants was independently associated
with development of perianal fistulas [25]. In contrast,
Annese et al. genotyped 360 consecutive CD patients for
the three main CARD15 mutations and found, by univariate
analysis, that patients who were carriers of any of the
CARD15 variants presented significantly higher incidence
of perianal disease [26]. Additionally, on multivariate
analysis, they observed that the R720W and G908P vari-
ants were positively and negatively associated with peria-
nal disease, respectively [26]. In our study, we did not find
any association between CARD15 mutations and risk of
developing Crohn0s perianal fistulas, or with time of peri-
anal fistula outbreak.
Fistula pathogenesis remains poorly understood, and
therefore management of patients with Crohn0s perianal
fistulas remains challenging. Nevertheless, there is evi-
dence suggesting that luminal bacteria might play a role in
development and maintenance of fistulas [18, 39–41].
Perhaps for this reason, antibiotics are a widely used and
recommended first-line treatment for fistulas in CD
patients, despite the near absence of randomized controlled
trials supporting this approach [4, 11]. As only 50% of
patients respond to this therapy, predictors for selection of
patients for antibiotic treatment are crucial [12–16]. This is
even more relevant if we remember that inadequate treat-
ment of perianal fistula may lead to fistula recurrence or
can result in the fistula progressing from simple to complex
form [17].
Regarding the response of perianal fistulas to antibiotics,
our results show that this is positively associated with
absence of CARD15 mutations (Table 1). It may be thought
that the best response to antibiotics observed in these
patients could be related to factors other than CARD15
genotype [2, 42–44]. This was ruled out by demonstrating
no significant differences between patients with and with-
out CARD15 variants in relation to other factors with a
Table 1 CARD15 mutations versus response of perianal fistulas to antibiotics
Total, n Response of perianal fistulas to antibiotics P OR (95% CI)*
Yes, n (%) No, n
Patients with CARD15 mutations 13 1 (7.7) 12 0.041 8.16 (0.97–68.74)
Patients without CARD15 mutations 42 17 (40.5) 25
OR odds ratio, CI confidence interval
* Calculated for the probability of response to antibiotics in patients without mutations compared with patients with mutations
Dig Dis Sci
123
potential effect on the response. In fact, we found no sig-
nificant differences between these two groups of patients
with regard to the characteristics of antibiotic therapy
(Table 2), concomitant medication (Table 3), proportion of
simple/complex fistulas or incidence of rectal mucosa
involvement by CD.
Angelberger et al., in a prospective study including 52 CD
patients with perianal fistulas treated with antibiotics, also
found better clinical response in patients without CARD15
mutations [16]. Nevertheless, in that work ciprofloxacin was
used as first-line treatment, while in our study all patients
received metronidazole, with or without ciprofloxacin
(association with ciprofloxacin in about half of the cases).
Thus, to our knowledge, our study is the first to show that
CARD15 genotype predicts the response of Crohn0s perianal
fistulas to treatment with metronidazole alone or in combi-
nation with ciprofloxacin. Based on our results, we suggest
that antibiotics should be questioned as first-line treatment in
perianal fistulas of CD patients with CARD15 variants.
Usually infliximab is recommended as second-line
treatment for Crohn0s perianal fistulas when first-line
treatment (antibiotics and/or azathioprine/6-mercaptopur-
ine) fails [4, 11]. Nevertheless, given the low response rate
of Crohn0s perianal fistulas to antibiotics and/or aza-
thioprine/6-mercaptopurine and the encouraging results of
infliximab in this setting, some authors consider a ‘‘top-
down’’ approach as an option for these patients [4, 11–16].
Our results, demonstrating that CARD15 genotype seems to
predict clinical response of perianal fistulas to antibiotics,
suggest that CARD15 genotype may be a factor in selection
of patients with perianal fistulas for a ‘‘top-down’’
approach. This interesting hypothesis needs to be tested in
randomized controlled studies.
There is, so far, no explanation for our observation of a
greater response to antibiotics in Crohn’s perianal fistulas
of CARD15 wild-type patients. However, we know that
CARD15 plays a role in bowel immunity by participating in
recognition of intestinal bacteria [21–24]. Thus, we can
speculate that, in CARD15 wild-type patients, endogenous
antimicrobial activity may synergize with antibiotics to
enhance their action, while in patients with CARD15
mutations this synergy does not occur. This speculation is
reinforced by some recent data that support an association
between CARD15 mutations and increased risk of several
infectious complications [45–47].
Some limitations of our study should be mentioned.
Firstly, characterization and evaluation of fistulas were
carried out retrospectively. Secondly, the size of the study
population is relatively small. Finally, this work was per-
formed in an academic referral hospital; therefore, our
results may not be applicable to institutions with different
patient populations.
Our work shows how gene identification strategies
combined with genotype–phenotype correlations might
identify prognostic markers to guide disease management.
In the future, randomized controlled studies are highly
warranted to confirm our results and to identify more
prognostic markers in order to define the optimum
approach for treatment of this challenging, and often seri-
ous, complication of CD.
Table 2 Characteristics of
antibiotic therapy: patients with
CARD15 mutations versus
patients without CARD15
mutations
With CARD15
mutations
Without CARD15
mutations
P
Ciprofloxacin alone (% of patients) 0 0 –
Metronidazole alone (% of patients) 44.4 50 0.803
Ciprofloxacin and metronidazole (% of patients) 55.6 50 0.783
Ciprofloxacin: dosage (mg/day) 1,000 ± 0 961 ± 138.7 0.551
Metronidazole: dosage (mg/day) 1,138 ± 356 932 ± 371 0.160
Ciprofloxacin: duration (weeks) 6.0 ± 2.4 6.1 ± 3.3 0.963
Metronidazole: duration (weeks) 8.0 ± 7.0 9.2 ± 8.0 0.687
Table 3 Concomitant
medication: patients with
CARD15 mutations versus
patients without CARD15
mutations
5-ASA 5-aminosalicylic acid
With CARD15
mutations (%)
Without CARD15
mutations (%)
P
Without medication 25.0 39.5 0.431
5-ASA 75.0 58.1 0.375
Steroids 25.0 7.0 0.148
Azathioprine, \3 months 9.0 19.0 0.251
Azathioprine, C3 months 25.0 9.0 0.162
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In conclusion, our study suggests that CARD15 muta-
tions are not associated with risk of developing Crohn0s
perianal fistulas, or with time of perianal fistula manifes-
tation. Nevertheless, in our series, CARD15 genotype
seems to predict clinical response of perianal fistulas to
antibiotic treatment. In fact, CD patients with perianal
fistulas and CARD15 mutations showed worse response to
antibiotic therapy with metronidazole alone or in combi-
nation with ciprofloxacin. Thus, in the light of our findings,
we propose that antibiotics should be questioned as first-
line treatment for Crohn0s perianal fistulas in patients with
CARD15 mutations. Such patient selection might avoid
delay in application of effective treatment and minimize
the risk of adverse events under antibiotic treatment.
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